SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
Returns on capital
SpyGlass Pharma, Inc. Common Stock management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
40.3%
avg 40.3%
ROIC
-38.6%
avg -38.6%
ROA
-34.4%
avg -34.4%
Analysis
ROE is currently the strongest return metric at 40.3% versus its period average of 40.3%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Patrick H. Mooney | CEO & Director | USD 659.63K | 52 | — | — |
Chetan Pujara | Chief Research & Development Officer | USD 523.39K | 56 | — | — |
Malik Y. Kahook | Co-Founder, President, Chief Medical Officer & Executive Chairman | USD 424.23K | 51 | — | — |
Mike Pinder | Vice President of Marketing | — | — | — | — |
Rachel Gilette | Vice President of Human Resources | — | — | — | — |
Shannon Trevino | General Counsel | — | — | — | — |
Glenn Sussman | Co-founder & Chief Technology Advisor | — | 62 | — | — |
James Robert Dennewill Jr. | Chief Operating Officer | — | 45 | — | — |
Jean-Frederic Viret | Chief Financial Officer | — | 60 | — | — |
Paul Yoo | Senior Vice President of Clinical Development | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does SpyGlass Pharma, Inc. Common Stock compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about SGP's management, answered from reported figures.
Who manages SGP?
SpyGlass Pharma, Inc. Common Stock (SGP) lists 10 active executives. The top listed executive is Chetan Pujara, Chief Research & Development Officer.
Continue the stock analysis
Jump to another research area for this company.